Fractional Flow Reserve and Instantaneous Free-wave Ratio Revascularization Strategies in Women
Launched by YALE UNIVERSITY · Oct 16, 2020
Trial Information
Current as of July 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The WOMEN FiRST (FFR iFR Revascularization Strategies Trial) study collects information from enrolled subjects to create a data repository. The data will be used to further elucidate recommendations for PCI of angiographically intermediate lesions (30-90% stenosis) in epicardial lesions in women by comparing FFR and iFR findings to findings of inducible ischemia on existing non-invasive stress imaging studies. Gender comparisons will also be made from archived and published research data sets from studies comprised up to 80% men. Data will also be stored long term for use in future undefine...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Female ≥ 18 years old at signing of informed consent
- • 2. Suspected myocardial ischemia or acute coronary syndrome
- • 3. Indication for non-invasive perfusion imaging study
- • 4. Indication for diagnostic catheterization
- • 5. Eligible for PCI
- • 6. Signed informed clinical procedural consent by subject or by surrogate
- Exclusion Criteria:
- • 1. Inability to receive adenosine or regadenoson (for example, severe reactive airway disease, marked hypotension, or advanced atrioventricular block without pacemaker.
- • 2. Severe cardiomyopathy (ejection fraction \<30%)
- • 3. Extremely tortuous or calcified coronary arteries precluding FFR/iFR measurements
- • 4. Patients with left main coronary artery disease requiring revascularization
- • 5. Female of child baring age should have negative pregnancy test
- • 6. Subject is pregnant or breast feeding, or planning to become pregnant
- • 7. Contraindication to non-invasive stress imaging including severe claustrophobia, renal disease with GFR \<30 where CMR is indication, any metal in the body which is a contraindication to CMR, allergy to gadolinium contrast
- • 8. ICD or PPM
About Yale University
Yale University, a prestigious Ivy League institution located in New Haven, Connecticut, is renowned for its commitment to advancing medical research and clinical innovation. With a rich history of academic excellence and a robust infrastructure for scientific inquiry, Yale serves as a leading sponsor for clinical trials aimed at improving patient care and developing new therapeutic approaches. The university's multidisciplinary teams of researchers and clinicians collaborate to conduct rigorous and ethical studies, leveraging cutting-edge technologies and methodologies to address critical health challenges. Through its dedication to fostering an environment of inquiry and discovery, Yale University plays a pivotal role in translating research findings into clinical practice, ultimately enhancing health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Haven, Connecticut, United States
Patients applied
Trial Officials
Elissa Altin, MD
Principal Investigator
Yale University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials